StemCells, Inc. Receives Authorization to Conduct World's First Neural Stem
Cell Trial in Spinal Cord InjuryPALO ALTO, Calif., Dec 7, 2010 (GlobeNewswire
via COMTEX) --
StemCells, Inc. (Nasdaq:STEM) announced today that is has received
authorization from Swissmedic, the Swiss regulatory agency for therapeutic
products, to initiate a Phase I/II clinical trial in Switzerland of the
Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem
cells) in chronic spinal cord injury. The trial is designed to assess both
safety and preliminary efficacy in patients with varying degrees of paralysis
who are three to 12 months post-injury, and will progressively enroll patients
based upon the severity of injury. Enrollment is expected to begin in early
2011.
